

## REFERENCES

- 1 Sharangi AB. Medicinal and therapeutic potentialities of tea (*Camellia sinensis* L.) – A review. *Food Res Int.* 2009; 42(5–6): 529–35.
- 2 Ho SC, Wu SP, Lin SM, Tang YL. Comparison of anti-glycation capacities of several herbal infusions with that of green tea. *Food Chem.* 2010; 122(3): 768–74.
- 3 de la Garza AL, Milagro FI, Boque N, Campion J, Martinez JA. Natural inhibitors of pancreatic lipase as new players in obesity treatment. *Planta Med.* 2011; 77(8): 773–85.
- 4 Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. *Drug Discov Today.* 2007; 12(19–20): 879–89.
- 5 Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. *Phytomedicine.* 2002; 9(1): 3–8.
- 6 Han LK, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of oolong tea. *Int J Obes Relat Metab Disord.* 1999; 23(1): 98–105.
- 7 Gondoin A, Grussu D, Stewart D, McDougall GJ. White and green tea polyphenols inhibit pancreatic lipase *in vitro*. *Food Res Int.* 2010; 43(5): 1537–44.
- 8 Persson IA, Josefsson M, Persson K, Andersson RG. Tea flavanols inhibit angiotensin-converting enzyme activity and increase nitric oxide production in human endothelial cells. *J Pharm Pharmacol.* 2006; 58(8): 1139–44.
- 9 Chiang E, Yan L, Ngar T. Analysis and evaluation of antioxidant properties of Thai herbal teas. *International Inter J Advance Sci & Art.* 2011; 2: 8–15.
- 10 Deetae P, Parichanon P, Trakunleewatthana P, Chanseetis C, Lertsiri S. Antioxidant and anti-glycation properties of Thai herbal teas in comparison with conventional teas. *Food Chem.* 2012; 133: 953–9.

- 11 Pinitsoontorn C, Suwantrai S, Boonsiri P. Antioxidant activity and oxalate content of selected Thai herbal teas. *KKU Res J* 2012; 17(1): 162–8.
- 12 Sangkitikomol W. Antioxidants in Thai herb, vegetable and fruit inhibit hemolysis and heinz body formation in human erythrocytes. 2012; Available from: <http://www.intechopen.com/books/oxidative-stress-environmental-induction-and-dietary-antioxidants/antioxidants-in-thai-herb-vegetable-and-fruit-inhibit-hemolysis-and-heinz-body-formation-in-human-e>.
- 13 Adisakwattana S, Intrawangso J, Hemrid A, Chanathong B, Mäkynen K. Extracts of edible plants inhibit pancreatic lipase, cholesterol esterase and cholesterol micellization, and bind bile acids. *Food Technol Biotechnol*. 2012; 50(1): 11–6.
- 14 Kim MS, Kim JK, Kim HJ, Moon SR, Shin BC, Park KW, et al. Hibiscus extract inhibits the lipid droplet accumulation and adipogenic transcription factors expression of 3T3–L1 preadipocytes. *J Altern Complement Med*. 2003; 9(4): 499–504.
- 15 Yingsukpisarn S. Angiotensin converting enzyme inhibition activity and antihypertensive effect of Thai medicinal plants. Thailand: Mahidol University; 2005.
- 16 Commins T, Sampanvejsobha S. Development of the tea industry in Thailand. *As J Food Ag–Ind*. 2008; 1(1): 1–16.
- 17 Braber Kd, Sato DM, Lee E. Farm and forestry production and marketing profile for tea (*Camellia sinensis*). Elevitch CR, editor: Permanent Agriculture Resources (PAR), PO Box 428, Hōlualoa, Hawai‘i 96725, USA; 2011.
- 18 Frey S. Which type of tea stains teeth the most. n.d.; Available from: <http://www.freysmiles.com/blog/view/which-type-of-tea-stains-teeth-the-most>.
- 19 Bansal DD, Singla A, Boparai R. Tea–Role in health and diseases. *NPR*. 2004; 3(3): 156–66.
- 20 Subramanian N, Venkatesh P, Ganguli S, Sinkar VP. Role of polyphenol oxidase and peroxidase in the generation of black tea theaflavins. *J Agric Food Chem*. 1999; 47(7): 2571–8.

- 21 Menet MC, Sang S, Yang CS, Ho CT, Rosen RT. Analysis of theaflavins and thearubigins from black tea extract by MALDI–TOF mass spectrometry. *J Agric Food Chem.* 2004; 52(9): 2455–61.
- 22 Del Rio D, Stewart AJ, Mullen W, Burns J, Lean ME, Brighenti F, et al. HPLC–MSn analysis of phenolic compounds and purine alkaloids in green and black tea. *J Agric Food Chem.* 2004; 52(10): 2807–15.
- 23 Yanagida A, Shoji A, Shibusawa Y, Shindo H, Tagashira M, Ikeda M, et al. Analytical separation of tea catechins and food–related polyphenols by high–speed counter–current chromatography. *J Chromatogr A.* 2006; 1112(1–2): 195–201.
- 24 Marston A. Role of advances in chromatographic techniques in phytochemistry. *Phytochemistry.* 2007; 68(22–24): 2786–98.
- 25 Sirikeratikul S. Thai FDA defines additional plants used as raw materials for herbal tea. Thailand: Global Agriculture Information Network (GAIN) Reports 2009.
- 26 Jirum J, Srihanam P. Oxidants and antioxidants: Sources and mechanism. *Acad J Kalasin Rajabhat University* 2011; 1(1): 59–70.
- 27 Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. *Curr Neuropharmacol.* 2009; 7(1): 65–74.
- 28 Fang YZ, Yang S, Wu G. Free radicals, antioxidants and nutrition. *Nutr.* 2002; 18(10): 872–9.
- 29 Bouayed J, Bohn T. Exogenous antioxidants – Double–edged swords in cellular redox state: Health beneficial effects at physiologic doses versus deleterious effects at high doses. *Oxid Med Cell Longev.* 2010; 3(4): 228–37.
- 30 Rietveld A, Wiseman S. Antioxidant effects of tea: evidence from human clinical trials. *J Nutr.* 2003; 133(10): 3285S–92S.
- 31 Ndhlala AR, Moyo M, Van Staden J. Natural antioxidants: fascinating or mythical biomolecules?. *Molecules.* 2010; 15(10): 6905–30.

- 32 Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem.* 2005; 53(10): 4290–302.
- 33 Horžić D, Komes D, Belščak A, Ganić KK, Iveković D, Karlović D. The composition of polyphenols and methylxanthines in teas and herbal infusions. *Food Chem.* 2009; 115(2): 441–8.
- 34 Karori SM, Wachira FN, Wanyoko JK, Ngure RM. Antioxidant capacity of different types of tea products. *Afr J Biotechnol.* 2007; 6(19): 2287–96.
- 35 Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. *Annu Rev Pharmacol Toxicol.* 2002; 42: 25–54.
- 36 Chiang ECW, Yan LP, TL N. Analysis and evaluation of antioxidant properties of Thai herbal teas. *IJASA.* 2011; 2(2): 8–15.
- 37 Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. *Diabetologia.* 2001; 44(2): 129–46.
- 38 Pun PB, Murphy MP. Pathological significance of mitochondrial glycation. *Int J Cell Biol.* 2012; 2012: 1–13.
- 39 Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification—a role in pathogenesis and antiproliferative chemotherapy. *Gen Pharmacol.* 1996; 27(4): 565–73.
- 40 Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. *J Clin Endocrinol Metab.* 2008; 93(4): 1143–52.
- 41 Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. *J Biol Chem.* 1994; 269(13): 9889–97.
- 42 Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. *Nutrients.* 2010; 2(12): 1247–65.
- 43 Nakagawa T, Yokozawa T, Terasawa K, Shu S, Juneja LR. Protective activity of green tea against free radical and glucose-mediated protein damage. *J Agric Food Chem.* 2002; 50(8): 2418–22.

- 44 WHO. Obesity and overweight. 2012; Available from: <http://www.who.int/mediacentre/factsheets/fs311/en/>.
- 45 Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. *Public Health Nutr.* 2009; 12(4): 497–506.
- 46 Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. *The Lancet.* 2005; 366(9491): 1059–62.
- 47 Malnick S, Knobler H. The medical complications of obesity. *Q J Med.* 2006; 99(9): 565–79.
- 48 Hossain P, Kavar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. *N Engl J Med.* 2007; 356(3): 213–5.
- 49 Chooprapawan C. National health examination survey 1991–1992 (NHES 1), Thailand Thailand health research institute; 1992.
- 50 Aekplakorn W. National health examination survey 2008–2009 (NHES 4), Thailand: Thailand Health Research Institute; 2009.
- 51 Schrauwen P, Westerterp KR. The role of high-fat diets and physical activity in the regulation of body weight. *Br J Nutr.* 2000; 84(4): 417–27.
- 52 Little TJ, Horowitz M, Feinle-Bisset C. Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. *Am J Clin Nutr.* 2007; 86(3): 531–41.
- 53 Willett WC. Dietary fat plays a major role in obesity: no. *Obes Rev.* 2002; 3(2): 59–68.
- 54 Astrup A. The role of dietary fat in the prevention and treatment of obesity. Efficacy and safety of low-fat diets. *Int J Obes Relat Metab Disord.* 2001; 25(Suppl 1): S46–50.
- 55 Miled N, Canaan S, Dupuis L, Roussel A, Riviere M, Carriere F, et al. Digestive lipases: from three-dimensional structure to physiology. *Biochimie.* 2000; 82(11): 973–86.
- 56 Fabricatore AN, Wadden TA. Treatment of obesity: an overview. *Clin Diabetes.* 2003; 21: 67–72.

- 57 Pronk NP, Wing RR. Physical activity and long-term maintenance of weight loss. *Obes Res.* 1994; 2(6): 587–99.
- 58 Klem ML, Wing RR, McGuire MT, Seagle HM, Hill JO. A descriptive study of individuals successful at long-term maintenance of substantial weight loss. *Am J Clin Nutr.* 1997; 66(2): 239–46.
- 59 Levy RL, Finch EA, Crowell MD, Talley NJ, Jeffery RW. Behavioral intervention for the treatment of obesity: strategies and effectiveness data. *Am J Gastroenterol.* 2007; 102(10): 2314–21.
- 60 Das SK, Chakrabarti R. Antiobesity therapy: emerging drugs and targets. *Curr Med Chem.* 2006; 13(12): 1429–60.
- 61 Chaput JP, St-Pierre S, Tremblay A. Currently available drugs for the treatment of obesity: Sibutramine and orlistat. *Mini Rev Med Chem.* 2007;7(1):3–10.
- 62 Scheen AJ. Sibutramine on cardiovascular outcome. *Diabetes Care.* 2011; 34 (Suppl 2): S114–9.
- 63 Tiss A, Lengsfeld H, Carrière F, Verger R. Inhibition of human pancreatic lipase by tetrahydrolipstatin: Further kinetic studies showing its reversibility. *J Mol Catal B: Enzym.* 2009; 58: 41–7.
- 64 Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. *Arch Fam Med.* 2000; 9(2): 160–7.
- 65 Halford JCG. Pharmacotherapy for obesity. *Appetite.* 2006; 46: 6–10.
- 66 Brethauer SA, Chand B, Schauer PR. Risks and benefits of bariatric surgery: current evidence. *Cleve Clin J Med.* 2006; 73(11): 993–1007.
- 67 Ivanova MG, Panaiotov I, Bois A, Gargouri Y, Verger R. Inhibition of pancreatic lipase by ovalbumin and  $\beta$ -lactoglobulin A at the air/water interface. *Journal of Colloid and Interface Science.* 1990; 136(2): 363–74.
- 68 Han LK, Kimura Y, Okuda H. Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet. *Int J Obes Relat Metab Disord.* 1999; 23(2): 174–9.
- 69 Tsujita T, Takaichi H, Takaku T, Sawai T, Yoshida N, Hiraki J. Inhibition of lipase activities by basic polysaccharide. *J Lipid Res.* 2007; 48(2): 358–65.

- 70 Tucci S. Phytochemicals in the control of human appetite and body weight. *Pharmaceuticals*. 2010; 3(3): 748–63.
- 71 Gooda Sahib N, Saari N, Ismail A, Khatib A, Mahomoodally F, Abdul Hamid A. Plants' metabolites as potential antiobesity agents. *Scientific World J*. 2012; 2012: 1–8.
- 72 Han LK, Kimura Y, Kawashima M, Takaku T, Taniyama T, Hayashi T, et al. Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor. *Int J Obes Relat Metab Disord*. 2001; 25(10): 1459–64.
- 73 Kim JK, So H, Youn MJ, Kim HJ, Kim Y, Park C, et al. *Hibiscus sabdariffa* L. water extract inhibits the adipocyte differentiation through the PI3-K and MAPK pathway. *J Ethnopharmacol*. 2007; 114(2): 260–7.
- 74 WHO, ISH. 1999 World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. *J Hypertens*. 1999; 17: 151–83.
- 75 Tanira MO, Al Balushi KA. Genetic variations related to hypertension: a review. *J Hum Hypertens*. 2005; 19(1): 7–19.
- 76 Aekplakorn W, Abbott-Klafter J, Khonputsa P, Tatsanavivat P, Chongsuvivatwong V, Chariyalertsak S, et al. Prevalence and management of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. *J Hypertens*. 2008; 26(2): 191–8.
- 77 Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension?. *Hypertension*. 2004; 44(1): 12–9.
- 78 Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, et al. The 2009 Canadian hypertension education program recommendations for the management of hypertension: Part 2—therapy. *Can J Cardiol*. 2009; 25(5): 287–98.
- 79 Natesh R, Schwager SL, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. *Nature*. 2003; 421(6922): 551–4.
- 80 Sturrock ED, Natesh R, van Rooyen JM, Acharya KR. Structure of angiotensin I-converting enzyme. *Cell Mol Life Sci*. 2004; 61(21): 2677–86.

- 81 Carretero OA. Novel mechanism of action of ACE and its inhibitors. *Am J Physiol Heart Circ Physiol*. 2005; 289(5): H1796–7.
- 82 Corradi HR, Schwager SL, Nchinda AT, Sturrock ED, Acharya KR. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. *J Mol Biol*. 2006; 357(3): 964–74.
- 83 Riviere G, Michaud A, Corradi HR, Sturrock ED, Ravi Acharya K, Coge V, et al. Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active. *Gene*. 2007; 399(1): 81–90.
- 84 Murray BA, FitzGerald RJ. Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. *Curr Pharm Des*. 2007; 13(8): 773–91.
- 85 Klabunde RE. Cardiovascular physiology concepts. 2007; Available from: <http://www.cvphysiology.com/Blood%20Pressure/BP015.htm>.
- 86 Fleming I. Signaling by the angiotensin-converting enzyme. *Circ Res*. 2006; 98(7): 887–96.
- 87 Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. *J Biol Chem*. 1995; 270(8): 3656–61.
- 88 Hooper N, Turner A. An ACE structure. *Nat Struct Biol*. 2003; 10: 155–57.
- 89 Alderman C. Adverse effects of the angiotensin-converting enzyme inhibitors. *Ann Pharmacother* 1996; 30(1): 55–61.
- 90 Wilson J, Hayes M, Carney B. Angiotensin-I-converting enzyme and prolyl endopeptidase inhibitory peptides from natural sources with a focus on marine processing by-products. *Food Chem*. 2011; 129(2): 235–44.
- 91 Dziuba J, Niklewicz M, Iwaniak A, Darewicz M, Minkiewicz P. Bioinformatic-aided prediction for release possibilities of bioactive peptides from plant proteins. *Acta alimentaria* 2004; 33(3): 227–35.
- 92 Matoba N, Usui H, Fujita H, Yoshikawa M. A novel anti-hypertensive peptide derived from ovalbumin induces nitric oxide-mediated vasorelaxation in an isolated SHR mesenteric artery. *Febs Lett*. 1999; 452(3): 181–4.

- 93 Pihlanto A, Akkanen S, Korhonen HJ. ACE-inhibitory and antioxidant properties of potato (*Solanum tuberosum*). Food Chem. 2008; 109(1): 104–12.
- 94 Yokozawa T, Oura H, Sakanaka S, Ishigaki S, Kim M. Depressor effect of tannin in green tea on rats with renal hypertension. Biosci Biotech Biochem. 1994; 58(5): 855–8.
- 95 Hara Y, Luo S, Wickremashinghe R, Yamanishi T. Uses and benefits of tea. Food Rev Inter. 1995; 11: 527–42.
- 96 Yang YC, Lu FH, Wu JS, Wu CH, Chang CJ. The protective effect of habitual tea consumption on hypertension. Arch Intern Med. 2004; 164(14): 1534–40.
- 97 Persson IA, Persson K, Hagg S, Andersson RG. Effects of green tea, black tea and Rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Public Health Nutr. 2010; 13(5): 730–7.
- 98 Jonadet M, Bastide J, Bastide P, Boyer B, Carnat AP, Lamaison JL. *In vitro* enzyme inhibitory and *in vivo* cardioprotective activities of hibiscus (*Hibiscus sabdariffa* L.). J Pharm Belg. 1990; 45(2): 120–4.
- 99 Ojeda D, Jimenez-Ferrer E, Zamilpa A, Herrera-Arellano A, Tortoriello J, Alvarez L. Inhibition of angiotensin convertin enzyme (ACE) activity by the anthocyanins delphinidin- and cyanidin-3-O-sambubiosides from *Hibiscus sabdariffa*. J Ethnopharmacol. 2010; 127(1): 7–10.
- 100 Muangnoi C. Bioaccessibility , cellular uptake and angiotensin I converting enzyme (ACE) inhibitory activity of triterpenoids from *Centella asiatica* (Linn.) Urban. Thailand: Mahidol University; 2007.
- 101 Ou B, Hampsch-Woodill M, Prior RL. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agric Food Chem. 2001; 49(10): 4619–26.
- 102 Fukumoto L, Mazza G. Assessing antioxidant and prooxidant activities of phenolic compounds. J Agric Food Chem. 2000; 48(8): 3597–604.
- 103 Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996; 239(1): 70–6.
- 104 Ainsworth EA, Gillespie KM. Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent. Nat Protoc. 2007; 2(4): 875–7.

- 105 Vinson JA, Howard Iii TB. Inhibition of protein glycation and advanced glycation end products by ascorbic acid and other vitamins and nutrients. *J Nutri Biochem.* 1996; 7(12): 659–63.
- 106 Choi SJ, Hwang JM, Kim SI. A colorimetric microplate assay method for high throughput analysis of lipase activity. *J Biochem Mol Biol.* 2003; 36(4): 417–20.
- 107 Schwager SL, Carmona AK, Sturrock ED. A high-throughput fluorimetric assay for angiotensin I-converting enzyme. *Nat Protoc.* 2006; 1(4): 1961–4.
- 108 Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. *J Agric Food Chem.* 2005; 53(6): 1841–56.
- 109 Low Dog T. Smart Talk on Supplements and Botanicals. *Alternative Compl Ther.* 2009; 15: 101–2.
- 110 Rusak G, Komes D, Likić S, Horžić D, Kovač M. Phenolic content and antioxidative capacity of green and white tea extracts depending on extraction conditions and the solvent used. *Food Chem.* 2008; 110(4): 852–8.
- 111 Turkmen N, Sari F, Velioglu YS. Effects of extraction solvents on concentration and antioxidant activity of black and black mate tea polyphenols determined by ferrous tartrate and Folin–Ciocalteu methods. *Food Chem.* 2006; 99(4): 835–41.
- 112 Nor Qhairul Izzreen MN, Mohd Fadzelly AB. Phytochemicals and antioxidant properties of different parts of *Camellia sinensis* leaves from Sabah Tea Plantation in Sabah, Malaysia. *Inter Food Res J.* 2013; 20(1): 307–12.
- 113 Kumoro AC, Hasana M, Singha H. Effects of solvent properties on the soxhlet extraction of diterpenoid lactones from *Andrographis paniculata* leaves. *SciAsia* 2009; 35: 306–9.
- 114 Yokozawa T, Dong E, Nakagawa T, Kashiwagi H, Nakagawa H, Takeuchi S, et al. *In Vitro* and *in vivo* studies on the radical-scavenging activity of tea. *J Agr Food Chem.* 1998; 46(6): 2143–50.
- 115 Chan EWC, Lim YY, Chong KL, Tan JBL, Wong SK. Antioxidant properties of tropical and temperate herbal teas. *J Food Compos Anal.* 2010; 23(2): 185–9.

- 116 Almajano MP, Carbó R, Jiménez JAL, Gordon MH. Antioxidant and antimicrobial activities of tea infusions. *Food Chem.* 2008; 108(1): 55–63.
- 117 Shukla S, Mehta A, Bajpai VK, Shukla S. *In vitro* antioxidant activity and total phenolic content of ethanolic leaf extract of *Stevia rebaudiana* Bert. *Food Chem Toxicol.* 2009; 47(9): 2338–43.
- 118 Brandle JE, Starratt AN, Gijzen M. *Stevia rebaudiana*: Its agricultural, biological, and chemical properties. *Can J Plant Sci.* 1998; 78(4): 527–36.
- 119 Kumar GS, Nayaka H, Dharmesh SM, Salimath PV. Free and bound phenolic antioxidants in amla (*Emblica officinalis*) and turmeric (*Curcuma longa*). *J Food Compos Anal.* 2006; 19(5): 446–52.
- 120 Poltanov EA, Shikov AN, Dorman HJ, Pozharitskaya ON, Makarov VG, Tikhonov VP, et al. Chemical and antioxidant evaluation of Indian gooseberry (*Emblica officinalis* Gaertn., syn. *Phyllanthus emblica* L.) supplements. *Phytother Res.* 2009; 23(9): 1309–15.
- 121 Tarwadi K, Agte V. Antioxidant and micronutrient potential of common fruits available in the Indian subcontinent. *Int J Food Sci Nutr.* 2007; 58(5): 341–9.
- 122 Nuengchamnong N, Krittasilp K, Ingkaninan K. Characterisation of phenolic antioxidants in aqueous extract of *Orthosiphon grandiflorus* tea by LC–ESI–MS/MS coupled to DPPH assay. *Food Chem.* 2011; 127(3): 1287–93.
- 123 Muñoz–Muñoz JL, García–Molina F, Ros E, Tudela J, García–Canovas F, Rodríguez–Lopez JN. Prooxidant and antioxidant activities of rosmarinic acid. *J Food Biochem.* 2012: 1–13.
- 124 Dent M, Dragović–Uzelac V, Penić M, Brnčić M, Bosiljkov T, B L. The effect of extraction solvents, temperature and time on the composition and mass fraction of polyphenols of dalmatian wild sage (*Salvia officinalis* L.). *Food Technol Biotechnol.* 2013; 51(1): 1–20.
- 125 Chan EWC, LP Y, Ngar T. Analysis and evaluation of antioxidant properties of Thai herbal teas. *Inter J Advance Sci & Art.* 2011; 2(2): 8–15.
- 126 Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr.* 2000; 130(Suppl 8S): 2073S–85S.

- 127 Williamson G, Holst B. Dietary reference intake (DRI) value for dietary polyphenols: are we heading in the right direction?. *Br J Nutr.* 2008; 99 (Suppl 3): S55–8.
- 128 Huo C, Wan SB, Lam WH, Li L, Wang Z, Landis–Piwowar KR, et al. The challenge of developing green tea polyphenols as therapeutic agents. *Inflammopharmacology.* 2008; 16(5): 248–52.
- 129 Khokhar S, Magnúsdóttir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United Kingdom. *J Agric Food Chem.* 2002; 50(3): 565–70.
- 130 Dearlove RP, Greenspan P, Hartle DK, Swanson RB, Hargrove JL. Inhibition of protein glycation by extracts of culinary herbs and spices. *J Med Food.* 2008; 11(2): 275–81.
- 131 Hsieh CL, Lin YC, Ko WS, Peng CH, Huang CN, Peng RY. Inhibitory effect of some selected nutraceutical herbs on LDL glycation induced by glucose and glyoxal. *J Ethnopharmacol.* 2005; 102(3): 357–63.
- 132 Peng X, Zheng Z, Cheng K–W, Shan F, Ren G–X, Chen F, et al. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. *Food Chem.* 2008; 106(2): 475–81.
- 133 Inami S, Takano M, Yamamoto M, Murakami D, Tajika K, Yodogawa K, et al. Tea catechin consumption reduces circulating oxidized low–density lipoprotein. *Int Heart J.* 2007; 48(6): 725–32.
- 134 Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid–lowering effect. *J Nutr Biochem.* 2007; 18(3): 179–83.
- 135 Juhel C, Armand M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium *in vitro*. *J Nutr Biochem.* 2000; 11(1): 45–51.
- 136 Nakai M, Fukui Y, Asami S, Toyoda–Ono Y, Iwashita T, Shibata H, et al. Inhibitory effects of oolong tea polyphenols on pancreatic lipase *in vitro*. *J Agric Food Chem.* 2005; 53(11): 4593–8.

- 137 Oi Y, Hou IC, Fujita H, Yazawa K. Antiobesity effects of Chinese black tea (Pu-erh tea) extract and gallic acid. *Phytother Res.* 2012; 26(4): 475–81.
- 138 Uchiyama S, Taniguchi Y, Saka A, Yoshida A, Yajima H. Prevention of diet-induced obesity by dietary black tea polyphenols extract *in vitro* and *in vivo*. *Nutrition.* 2011; 27(3): 287–92.
- 139 Lee YM, Kim YS, Lee Y, Kim J, Sun H, Kim JH, et al. Inhibitory activities of pancreatic lipase and phosphodiesterase from Korean medicinal plant extracts. *Phytother Res.* 2012; 26(5): 778–82.
- 140 Bhandari U, Sharma JN, Zafar R. The protective action of ethanolic ginger (*Zingiber officinale*) extract in cholesterol fed rabbits. *J Ethnopharmacol.* 1998; 61(2): 167–71.
- 141 Bhandari U, Kanojia R, Pillai KK. Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia in diabetic rats. *J Ethnopharmacol.* 2005; 97(2): 227–30.
- 142 Sriplang K, Adisakwattana S, Rungsipipat A, Yibchok-Anun S. Effects of *Orthosiphon stamineus* aqueous extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. *J Ethnopharmacol.* 2007; 109(3): 510–4.
- 143 Hussin M, Hamid AA, Mohamad S, Saari N, Bakar F, Dek SP. Modulation of lipid metabolism by *Centella asiatica* in oxidative stress rats. *J Food Sci.* 2009; 74(2): H72–8.
- 144 N Sharma, R Mogra, Upadhyay B. Effect of stevia extract intervention on lipid profile. *Ethno-Med.* 2009; 3(2): 137–40.
- 145 Liu F, Wei Y, Yang XZ, Li FG, Hu J, Cheng RF. Hypotensive effects of safflower yellow in spontaneously hypertensive rats and influence on plasma renin activity and angiotensin II level. *Acta Pharmaceutica Sinica.* 1992; 27(10): 785–7.
- 146 Hsu YH, Liu JC, Kao PF, Lee CN, Chen YJ, Hsieh MH, et al. Antihypertensive effect of stevioside in different strains of hypertensive rats. *Chin Med J.* 2002; 65(1): 1–6.

- 147 Chan P, Xu DY, Liu JC, Chen YJ, Tomlinson B, Huang WP, et al. The effect of stevioside on blood pressure and plasma catecholamines in spontaneously hypertensive rats. *Life Sci.* 1998; 63(19): 1679–84.
- 148 Chan P, Tomlinson B, Chen YJ, Liu JC, Hsieh MH, Cheng JT. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. *Br J Clin Pharmacol.* 2000; 50(3): 215–20.
- 149 Melis MS. Influence of calcium on the blood pressure and renal effects of stevioside. *Braz J Med Biol Res.* 1992; 25(9): 943–9.
- 150 Matsubara T, Bohgaki T, Watarai M, Suzuki H, Ohashi K, Shibuya H. Antihypertensive actions of methylripariochromene A from *Orthosiphon aristatus*, an Indonesian traditional medicinal plant. *Biol Pharm Bull.* 1999; 22(10): 1083–8.
- 151 Ohashi K, Bohgaki T, Shibuya H. Antihypertensive substance in the leaves of kumis kucing (*Orthosiphon aristatus*) in Java Island. *J Pharm Soc Jpn.* 2000; 120(5): 474–82.
- 152 Dong J, Xu X, Liang Y, Head R, Bennett L. Inhibition of angiotensin converting enzyme (ACE) activity by polyphenols from tea (*Camellia sinensis*) and links to processing method. *Food Funct.* 2011; 2(6): 310-9.
- 153 Kang WS, Lim IH, Yuk DY, Chung KH, Park JB, Yoo HS, et al. Antithrombotic activities of green tea catechins and (–)-epigallocatechin gallate. *Thromb Res.* 1999; 96(3): 229–37.
- 154 Lorenz M, Wessler S, Follmann E, Michaelis W, Dusterhoft T, Baumann G, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. *J Biol Chem.* 2004; 279(7): 6190–5.
- 155 Negishi H, Xu JW, Ikeda K, Njелеkela M, Nara Y, Yamori Y. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. *J Nutr.* 2004; 134(1): 38–42.

- 156 Duffy SJ, Keaney JF, Jr., Holbrook M, Gokce N, Swerdloff PL, Frei B, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. *Circulation*. 2001; 104(2): 151–6.
- 157 Muangnongwa S. Effect of expressed juice of fresh *Centella asiatica* (L.) Urban leaves on cardiovascular function in DOCA–salt hypertensive rats. Thailand: Mahidol University; 2004.